- Home
- MBWM vs GLUE Comparison
MBWM vs GLUE Comparison
Compare MBWM & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | GLUE |
|---|---|---|
| Founded | 1997 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBWM | GLUE |
|---|---|---|
| Price | $60.30 | $11.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $55.67 | $32.00 |
| AVG Volume (30 Days) | 79.5K | ★ 1.0M |
| Earning Date | 04-21-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 10.95 | N/A |
| EPS | ★ 2.82 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | $20.28 | N/A |
| Revenue Next Year | $4.67 | $2.45 |
| P/E Ratio | ★ $21.11 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $42.75 | $7.09 |
| 52 Week High | $62.95 | $25.77 |
Technical Indicators
Market Signals| Indicator | MBWM | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 50.33 | 29.33 |
| Support Level | $58.49 | N/A |
| Resistance Level | $62.67 | $15.00 |
| Average True Range (ATR) | 1.28 | 0.65 |
| MACD | -0.20 | -0.01 |
| Stochastic Oscillator | 37.27 | 10.56 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).